Resources
22 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 8/4/2021 (updated 4/2/2024)
This program brief highlights the Alliance for Prevention and Wellness (APW) use of Overdose Detection Mapping Application Program (ODMAP) data to target a broad range of substance use prevention and education activities to ZIP codes with the highest rate of overdoses. Source: Bureau of Justice Assistance (BJA)-Supported Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP).
Posted 7/28/2021 (updated 4/2/2024)
This handbook is intended to address this particular set of workplace issues- namely those that arise from experiences of loss, grief and trauma. These issues can surface within the workplace itself, or can be imported into the work setting from workers’ personal lives. This handbook will be useful for managers, supervisors and human resource specialists who are interested in developing their understanding of how the very real issues associated with loss, grief and trauma can be tackled when they show up in work settings. This handbook is a blend of theory and practice, and can be used as a resource for building effective policies and practical responses to the complexities of managing grief, loss and bereavement in the workplace.
Posted 3/19/2020 (updated 3/28/2024)
To help local leaders respond to this epidemic, USDA has worked to build infrastructure for prevention, treatment and recovery, facilitate partnerships, and drive innovation in rural communities.
Posted 11/21/2019 (updated 3/28/2024)
The goal of this booklet is to get us all to take the issue of overamping seriously and to bring attention to it as much as other kinds of “overdoses,” and also to recognize all the smart things people already do to keep themselves and their friends safe.
Posted 11/21/2019 (updated 3/28/2024)
The purpose of this protocol is to provide guidelines for the use of Naloxone and to reduce the number of fatalities.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.